IL-23 Archives - Drugs in Context

Home IL-23

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study

Tiago Torres, Paulo Varela, Pedro Mendes Bastos, Sofia Magina, Martinha Henrique, Paulo Ferreira

Article Type

Original Research

Published

18 Mar 2024

This study aimed to evaluate the effectiveness of tildrakizumab in treating moderate-to-severe psoriasis within a real-world setting over a 52-week period in Portugal.

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience

Giacomo Caldarola, Arianna Zangrilli, Gerardo Palmisano, Mauro Bavetta, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Luca Bianchi, Clara De Simone, Ketty Peris

Article Type

Review

Published

13 Apr 2023

This multicentre, retrospective study evaluates the efficacy and safety of risankizumab in a population of psoriatic patients with palmoplantar involvement over a 52-week treatment period.